Short Bowel Syndrome: Human Intestinal Organoids to Investigate the Different Efficacy of the GLP-2 Analogue Teduglutide in Pediatric Patients

What this Trial Is About

Researchers are studying pediatric patients with short bowel syndrome, a rare condition where significant intestinal removal causes problems with nutrient absorption and reliance on parenteral nutrition. This trial aims to understand why children respond differently to teduglutide, a drug that helps the intestine adapt and absorb nutrients better. The study uses human intestinal organoids, which are lab-grown mini-intestines from patient tissue, to explore biological reasons behind varied treatment responses. The study compares organoids treated with teduglutide to untreated ones to assess changes in intestinal structure, cell growth, gene activity, and nutrient absorption. Organoids come from intestinal tissue collected during routine surgeries and are grown and treated in the lab. No experimental treatment is given directly to the children participating; the focus is on lab testing of their tissue samples. Participants provide tissue samples during standard surgical procedures, and their organoids are studied in vitro for up to seven days with and without teduglutide exposure. Researchers measure organoid size, shape, lumen size, architecture, and integrity to evaluate the drug's effects. This work aims to improve understanding of teduglutide's impact and support more personalized treatments for children with short bowel syndrome in the future.

TED_ORG: Study on Short Bowel Syndrome